RELATIONSHIP BETWEEN DRUG USE IN PREGNANCY AND TERATOGENICITY
Abstract views: 121
/ 
PDF downloads: 42
DOI:
https://doi.org/10.5281/zenodo.15108848%20%20%20Abstract
The rate of drug use during pregnancy has been increasing in recent years and it is increasing unconsciously day by day. Mitcell et al. reported that more than 70% of women used at least 1 over-the-counter (OTC) drug in the first trimester of pregnancy and approximately 50% used 1 or more drugs. Especially in the first trimester of pregnancy, drug use has increased 4 or more times in the last 30 years on a package basis, and the rate of drug use in pregnant women has increased up to 3 times. At the same time, the rate of prescription drug use has increased by more than 60 per cent in the last 30 years. Pregnancy is generally defined as a temporary and long-term process in women's lives. Certain physiological and anatomical differences are observed in the mother's body from the early stages of pregnancy to the birth process and even in later processes. With these physiological differences, the use of drugs is of great importance for the expectant mother and fetus, as the teratogenic effects of many drugs on the market have not been fully resolved. If the teratogenic effects of drugs are ignored, harmful effects are observed for the foetus, whereas if the teratogenic effect is taken as a basis, it may lead to consequences such as inability to treat the expectant mother and termination of pregnancy even if it is not desired. For this reason, health personnel such as pharmacists, doctors and nurses should be more careful in this regard.
References
-Mitcell AA, Gilboa SM, Werler MM, et al.; National Birth Defects Prevemtion Study. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am J Obstet Gynecol. 205:51, 2011.
-Centers For Disease Control and Prevention. National Center on Birth Defects and Developmental Disabilities. Medication use during pregnancy, with particular focus on prescription drugs. 1976-2008, 2013.
-Adam MP, Polifka JE, Friedman JM. Evolving knowledge of the teratogenicity of medications in human pregnancy. Am J Med Genet C Semin Med Genet. 157:175-182, 2011.
-Schimmer BP, Parker KL. Contraception and pharmacotherapy of obstetrical and gynecological disoders. In: Brunton LL, Chabner BA, Knollmann BC, eds. Goodman&Gilman’s The Pharmacological Basis of Therapeutics. 12th ed. New York: McGraw-Hill;2011.
-FDA, Center for Drug Evaluation and Research. Guidance for industry. Pharmacokinetics in pregnancy –study design, data analysis and impact on dosing and labeling March 4,2013.
-Centers for Disease Control and Prevention.Medications and pregnancy. March 13,2013.
-Albayrak A, Demir A & Sezik M. Gebe kadınların gebelik sürecinde ilaç kullanımı hakkında bilgi, tutum ve davranışlarının değerlendirilmesi. Journal of Faculty of Pharmacy of Ankara University, 48(1):109-117,2024. 7
-World Health Organization (WHO). Erişim tarihi: 10 Nisan 2018.
-Holloway K, van Dijk L. The World Medicines Situation 2011-Rational use of medicines. WHO, Geneva. 2011.
-Öztürk Z. Gebelikte İlaç Kullanımı ve Risk Değerlendirmesi: Beni kategorize etme. Zeynep Kamil Tıp Bülteni. 49:109-12, 2018.
-Kamuhabwa A, Jalal R. Drug use in pregnancy: Knowledge of drug dispensers and pregnant women in Dar es Salaam,Tanzania. Indian J Pharmacol. 43:345-9, 2011.
-Duman M. Different Risk Categorizations Related to the Use of Drugs During Pregnancy. Türkiye Klinikleri J Gynecol Obst-Special Topics. 6:12-7, 2013.
-Saygılı M, Özer Ö. Hekimlerin akılcı ilaç kullanımına yönelik bilgi, tutum ve davranışlarının değerlendirilmesi. Hacettepe Sağlık İdaresi Dergisi. 18:35-46, 2015.
-Miral M, K.Beji N. Gebelikte ilaç kullanımı ve danışmanlık. Sağlık Bilimleri ve Meslekleri Dergisi. 4:142-8, 2017.
-Sirakov M, Mircheva J. Are herbs safe during pregnancy and breastfeeding. Suvr Med (Sofiia). 51:33-8, 2012.
-Sel G, Küçük H, Harma M İ, et al. Teratojenite Riskli İlaç Kullanan İlk Trimester Gebelerin, Gebeliklerinin Devamı Konusundaki Tercihleri. Tıp Araştırmaları Arşivi. 2:17-20, 2017.
-Kayaalp SO. Rasyonel Tedavi Yönünden Tıbbi Farmakoloji. 13. Baskı. Ankara; Pelikan Yayınevi. 2012.
-Nagi AH. Placenta examination and pathology. Biomedica. 27:81-9, 2011.
-Öztürk Z. Approaching Pregnant Women using Medicine: Risk of Teratogenicity and Counselling Services. Sted. 24:201-5, 2014.
-Özbudak, H, Ünal Z, Sabuncuoğlu, S. Gebelikte Non-Steroidal Antiinflamatuvar İlaçların Kullanımının Değerlendirilmesi, Marmara Pharmaceutical Journal. 20:72-9, 2016.
-Kaplan YC, Can H, Demir Ö, et al. A new era begins in risk communication regarding drug use in pregnancy: Changes in FDA pregnancy risk categories. Turkish Journal of Family Practice.18:195-8, 2014.
-Orer HS. Teratojen Ajanlar. InTemel Kadın Hastalıkları ve Doğum Bilgisi. 3. Baskı (Ed Günalp S): 1706-1709. Ankara, Güneş Tıp Kitapevi, 2014.
-Tel E, Sabuncuğlu S. Gebelikte Tiroid Fonksiyon Bozukluğunda Kullanılan İlaçlar ve Toksisiteleri. FABAD Journal Pharmaceutical Sciences. 42:239-48, 2017.
-Costa DB, Coelho HL, Santos DB. Use of medicines before and during pregnancy: prevalence and associated factors. Cad Saude Publica. 33:1-14, 2017.
-James HK, Anthony RS. Thalidomide: The Tragedy of Birth Defects and the Effective Treatment of Disease. Tox Sci 122(1); 1–6, 2011.
-Schumacher HA. Comparison of the teratogenic activity of thalidomide in rabbits and rats. J Pharmacol Exp Ther 160; 189–199, 1968.
-Smithells RW, Newman CHG. Recognition of thalidomide defects. J Med Genet 29:716-723, 1992.
-Lenz W, Knapp K. Foetal malformations due to Thalidomide. German Med 7:253–8, 1962.
-McBride WG. Thalidomide and congenital abnormalities. Lancet. ii:1358, 1961.
-Curran, W. The thalidomide tragedy in Germany: The end of a historic medicolegal trial. New Engl J Med, 284: 481-482, 1971.
-Frederiksen, MC. The New FDA Pregnancy Labeling Requirements for Drugs. J Midwifery Womens Health 56:303–7,2011.
-Addis A, Sharabi S, Bonati M. Risk Classification systems for drug use during pregnancy, are they a reliable source of information? Drug Saf 23(3):245–253, 2000.
-Lo WY, Friedman JM. Teratogenicity of recently introduced medications in human pregnancy. Obstet Gynecol 100(3):465–473, 2002.
-Costantine MM. Physiologic and pharmacokinetic changes in pregnancy. Frontiers in pharmacology 5:65, 2014.
-Dawes M, Chowienczyk PJ. Drugs in pregnancy. Pharmacokinetics in pregnancy. Best practice & Research Clinical Obstetrics & Gynaecology 15(6):819-26, 2001.
-Akici A, Tamirci M, Gören MZ. The Impacts of the physiological changes occurring during pregnancy on pharmacokinetic mechanisms. Clinical and Experimental Health Sciences; 2017.
-Kayaalp SO, Akici A. 12. Konu: İlaçların Toksik Tesirleri ve Toksikolojinin Temel Kavramları. Akılcı Tedavi Yönünden Tıbbi Farmakoloji1. Ankara: 117-8.5,2012.
-Klotz U. Paracetamol (acetaminophen) - a popular and widely used nonopioid analgesic. Arzneimittelforschung. 62(8):355-9, 2012.
-Rebordosa C, Kogevinas M, Sorensen HT, et al. Prenatal exposure to paracetamol and risk of wheezing and asthma in children: a birth cohort study. Int J Epidemiol 37:583–90, 2008.
-Liew Z, Yuan Y, Meng Q, et al. Prenatal exposure to acetaminophen and childhood asthmatic symptoms in a population-based cohort in Los Angeles, California. Int J Environ Res Public Health. 18(19):10107, 2021.
-Kristensen DM, Hass U, Lesne L, et al. Intrauterine exposure to mild analgesics is a risk factor for development of male reproductive disorders in human and rat. Hum Reprod. 26(1):235-44, 2011.
-Jensen MS, Rebordosa C, Thulstrup AM, et al. Maternal use of acetaminophen, ibuprofen, and acetylsalicylic acid during pregnancy and risk of cryptorchidism. Epidemiology 21:779-85, 2010.
-Fisher BG, Thankamony A, Hughes IA, et al. Prenatal paracetamol exposure is associated with shorter anogenital distance in male infants. Hum Reprod. 31(11):2642-50, 2016.
-Stergiakouli E, Thapar A, Smith GD. Association of acetaminophen use during pregnancy with behavioral problems in childhood. JAMA Pediatrics 170(10):964-70, 2016.
-Henderson JT, Whitlock EP, O’Connor E, et al. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med.160(10):695-703,2014.
-Couto AC, Ferreira JD, Pombo-de-Oliveira MS, et al. Collaborative Study Group of Infant Acute Leukemia. Pregnancy, maternal exposure to analgesic medicines, and leukemia in Brazilian children below 2 years of age. Eur J Cancer Prev. 24(3):245-52, 2015.
-Sharpe CR, Franco EL. Use of dipyrone during pregnancy and risk of Wilms’ tumor. Brazilian Wilms’ Tumor Study Group. Epidemiology 7:533-5,1996.
-da Silva Dal Pizzol T, Schüler-Faccini L, Mengue SS, et al. Dipyrone use during pregnancy and adverse perinatal events. Arch Gynecol Obstet. 279(3):293-7, 2009.
-Li DK, Liu L, Odouli R. Exposure to non-steroidalanti-inflammatory drugs during pregnancy and riskof miscarriage: Population based cohort study. BMJ 327(7411):368,2003.
-Campbell S, Clohessy A, O’Brien C, et al. Fetal anhydramnios following maternal non-steroidal anti-inflammatory drug use in pregnancy. Obstet Med. 10(2):93-5, 2017.
-Committee Opinion No. 711: Opioid use and opioid use disorder in pregnancy. Obstet Gynecol. 130(2):e81-e94, 2017.
-Baldacchino A, Arbuckle K, Petrie DJ, et al. Neurobehavioral consequences of chronic intrauterine opioid exposure in infants and preschool children: A systematic review and meta-analysis. BMC Psychiatry. 8:14-104, 2014.
-Dean L, Kane M. Codeine Therapy and CYP2D6 Genotype. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, eds. Medical Genetics Summaries. Bethesda (MD): National Center for Biotechnology Information (US); September 20, 2012.
-Jentink J, Loane MA, Dolk H, et al. Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med. 362:2185–93, 2010.
-Huybrechts KF, Palmsten K, Avorn J, et al. Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med. 370(25):2397-407, 2014.
-Ozturk Z, Olmez E, Gurpinar T, et al. Pregnancy outcomes following the use of thiocolchicoside. Reprod Toxicol 60:129-32, 2016.
-Cohen MM, Levy, Eliakim M. A cytogenetic evaluation of long-term therapy in the treatment of Familial Mediterranean fever (FMF). Am J Med Sci 274:147-52, 1977.
-Yasar O, Iskender C, Kaymak O, et al. Retrospective evaluation of pregnancy outcomes in women with familial Mediterranean fever. J Matern Fetal Neonatal Med 27(7):733-6, 2014.
-Götestam SC, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 75:795–810, 2016.
-Smets K, Zecic A, Willems J. Ergotamine as a possible cause of Mobius sequence: Additional clinical observation. J Child Neurol 19(5):398, 2004.
-Bérard A, Kori S. Dihydroergotamine (DHE) use during gestation and the risk of adverse pregnancy outcomes. Headache. 52(7):1085-93, 2012.
-Demirel G, Oguz SS, Erdeve O, et al. Unilateral renal agenesis and urethral atresia associated with ergotamine intake during pregnancy. Ren Rail. 34(5):643-4, 2012.
-Evans EW, Lorber KC. Use of 5-HT1 agonists in pregnancy. Ann Pharmacother. 42(4):543-9, 2008.
-Marchenko A, Etwel F, Olutunfese O, et al. Pregnancy outcome following prenatal exposure to triptan medications: a meta-analysis. Headache 55(4):490-501, 2015.
-Amzajerdi, A. Keshavarz, M. Montazeri, A. et al. Effect of mint aroma on nausea, vomiting and anxiety in pregnant women. J. Fam. Med. Prim. Care. 8:2597–2601, 2019.
-Muñoz Balbontín Y, Stewart D, Shetty A, et al. Complementary and Alternative Medicine: Review Herbal Medicinal Product Use During Pregnancy and the Postnatal Period: A Systematic Review. Obstet Gynecol 133:920–32, 2019.
-Ziaei S, Hantoshzadeh S, Rezasoltani P, et al. The effect of garlic tablet on plasma lipids and platelet aggregation in nulliparous pregnants at high risk of preeclampsia. Eur J Obstet Gynecol Reprod Biol. 99:201-6, 2001.
-Nazari S, Rameshrad M, Hosseinzadeh H. Toxicological Effects of Glycyrrhiza glabra (Licorice): A Review Phytother Res 31:1635-50, 2017.
-Dante G, Bellei G, Neri I, et al. Herbal therapies in pregnancy: what works? Curr Opin Obstet Gynecol. 26:83-91, 2014.
-Kennedy DA, Lupattelli A, Koren G, et al. Herbal medicine use in pregnancy: results of a multinational study. BMC Complementary and Alternative Medicine 13:355-45, 2013.
-Dante G, Pedrielli G, Annessi E, et al. Herb remedies during pregnancy: a systematic review of controlled clinical trials. J Matern Fetal Neonatal Med. 26:306-12, 2013.
-Sarecka-Hujar B, Szulc-Musioł B. Herbal Medicines Are They Effective and Safe during Pregnancy? Pharmaceutics. 14:171, 2022.
-Ozgoli G, Goli M, Simbar M. Effects of ginger capsules on pregnancy, nausea, and vomiting. J Altern Complement Med. 15:243-46, 2009.
-Belica AL, Ćetković NB, Milić NB, et al. Herbal Therapy in Pregnancy-What to Expect When You Expect? Natural Product Communications. 12:1957–69, 2017.
-Simpson M, Parsons M, Greenwood J, et al. Raspberry leaf in pregnancy: its safety and efficacy in labor. J Midwifery Womens Health. 46:51-9, 2001.
-Mahmoudian A, Rajaei Z, Haghir H, et al. Effects of valerian consumption during pregnancy on cortical volume and the levels of zinc and copper in the brain tissue of mouse fetus. Zhong Xi Yi Jie He Xue Bao. 10:424-9, 2012.
-Kahyaoğlu F, Gökçimen A, Demirci B. Investigation of the embryotoxic and teratogenic effect of Hypericum perforatum in pregnant rats. Journal of Turkish Society of Obstetric and Gynecology. 15:87-90, 2018.
-Magan P, Pratten M, Magan et al. Effects of the Herbal Product Curcumin on Cardiomyocytes in Micromass Culture and the Potential Role It May Play in Pregnancy and Development. Cureus 15:51132, 2023.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Journal of the Turkic World Women Studies
This work is licensed under a Creative Commons Attribution 4.0 International License.
